Dr. Earle Burgess on the next steps with PARP inhibitors in prostate cancer

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

The addition of SBRT to upfront abiraterone acetate and prednisone (AAP) reduced the risk of disease progression or death by 65% compared with AAP alone in patients with oligometastatic castration-resistant prostate cancer.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

UCSF is West Coast leader for the innovative, minimally invasive treatment for prostate cancer patients.

In the first article of this series, Nilay Gandhi, MD, explains the treatment and management of patients with advanced/metastatic prostate cancer and details the options for androgen deprivation therapy.